BioMelbourne Network
Progressing BioIndustry

News and Opinions

Previous1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

2015

June

Circadian receives IND approval from FDA to initiate clinical trial of OPT - 302 for wet AMD patients

15 June 2015.  ASX and Media ReleaseCircadian receives IND approval from FDA to initiate clinical trial of OPT-302 for wet AMD patients Melbourne, Australia – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) through its wholly owned subsidiary Opthea Pty Ltd is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to... read more…

Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D

15 June 2015 A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia’s largest biotechnology company. Australia has a skilled workforce, quality education and strong research base. These are the pillars ... read more…

Antisense Therapeutics announces license deal with Sweden based Cortendo

12 June 2015.  Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for ... read more…

Commonwealth provides $10.6 million investment in projects for accelerating commercialisation

11 June 2015.  Eighteen Australian companies will receive grants to propel their innovative ideas from the drawing board into the marketplace under the Australian Government’s Accelerating Commercialisation programme.Industry and Science Minister Ian Macfarlane said the first round of $10.6 million in funding under the Accelerating Commercialisation element of the Australian Government’s $484.2... read more…

Design + Industry - "We’re Good Design Award Winners!"

10 June 2015.  The D+I team enjoyed another great night celebrating their design achievements at the 2015 Good Design Awards. With two prestigious Design Awards and three Design Selections they are thrilled with their winning results.Their work with Siemens Healthcare Diagnostics and Universal Biosensors for the Xprecia Stride™ Coagulation System won a Good Design Award in the Medical and Scien... read more…

LBT Begins Key U.S. Trial of APAS Technology

9 June 2015.  Australian medical technology company LBT Innovations Limited (ASX: LBT) has commenced the United States phase of the clinical trial programme for its pioneering culture-plate intelligent image analysis technology, APAS® (Automated Plate Assessment System). The trial now underway at TriCore Reference Laboratories in New Mexico is in support of LBT’s 510(k) de novo submission to t... read more…

Global Kinetics Corporation Closes $14.8 million Capital Raising

2 June 2015.  Australian health technology company Global Kinetics Corporation has successfully raised $14.8 million to rapidly progress the company’s global commercialisation strategy for its lead Parkinson’s KinetiGraph™ (PKG™) mobile health technology. Foundation investor Brandon Capital Partners has contributed further capital in the funding round. New investors include institutional inve... read more…

Aussie Hearing Invention Wins Coveted Awards

2 June 2015.  On May 29 2015, Good Design Australia presented Melbourne hearing device company Blamey Saunders hears with the inaugural Social Innovation award, in recognition of the IHearYou® system's role in creating a better society by removing barriers to quality hearing aids; barriers like cost, stigma and distance to service providers. Judges called it: “An innovation that not only has a ... read more…
May

Gordagen Commences Clinical Trial Program for Evidence-Based Nutraceuticals

28 May 2015.  Gordagen Pharmaceuticals, a privately-held company commercializing evidence-based nutraceuticals and pharmaceuticals, today announced that it has received approval from Bellberry Limited, Australia’s National Human Research Ethics Committee (HREC) to commence its Phase I study of natural tocotrienols.   The Single Ascending Dose (“SAD”) study will assess the safety, tolerability a... read more…

New Awards Recognise Women in Leadership in Biotech, Medtech and Healthcare Technology

22 May 2015.  Australian women do comparatively well in biotechnology, medtech and health care technology – with 11.1% of companies in the sector in the ASX 200 having female executive key management personnel and 11.9% in the ASX 500.However, in recognition that these figures need to improve and to honor outstanding women in the sector, The BioMelbourne Network will, this Friday, announce its ... read more…